Evotec (NASDAQ:EVO) Shares Gap Down – Here’s What Happened

Evotec SE (NASDAQ:EVO)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $4.70, but opened at $4.57. Evotec shares last traded at $4.57, with a volume of 5,992 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Evotec in a report on Thursday, November 7th.

Evotec Trading Down 4.3 %

The firm has a fifty day moving average of $4.44 and a 200-day moving average of $4.04. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.

Institutional Trading of Evotec

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in shares of Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after buying an additional 602,858 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Evotec in the 3rd quarter valued at about $104,000. Finally, Mediolanum International Funds Ltd bought a new stake in shares of Evotec in the 3rd quarter valued at about $512,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.